To further understand the potential associations between those 13 5hmC-modified marker genes and R-CHOP treatment response, we investigated their mRNA expression profiles and compared them to that of B-lymphocyte antigen CD20 (MS4A1), a rituximab target gene, in 48 DLBCL patients from the TCGA-DLBC dataset. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.